Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QETDI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
mRG004A
|
|||||
| Synonyms |
MRG004A; MRG004
Click to Show/Hide
|
|||||
| Organization |
Synaffix (Originator);Miracogen
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
MAB804
|
Antibody Info | ||||
| Antigen Name |
Tissue factor (F3)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
BCN-Val-Cit linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|